MELANOMA
EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
PI: Marvin J. Feldman
For more information about ongoing clinical trials at the Alvin & Lois Lapidus Cancer Institute, please contact the oncology research team at 410-601-6120.
Sinai Hospital of Baltimore
2401 West Belvedere Ave.
Baltimore, Maryland 21215,
(T) 410-601-6120
|